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Purpose: A variety of vena caval filters (VCFs) are available for usage. The choice of filter 
type depends on physician preference and certain patient variables. An evaluation of the 
different VCFs used in our institution was done to compare their efficacy and complication 
rates. 
Methods: The medical records of all patients who underwent insertion of a VCF from 
January 1987 to June 1993 at the University of Iowa Hospitals & Clinics and the affiliated 
Veterans Administration Medical Center were reviewed. One hundred ninety-nine VCFs 
were placed in 196 patients (123 males, 73 females), with a mean age of 61 years (range 
13 to 87 years). Thirty-five (18%) VCFs (30 stainless teel Greenfield filters [SGFs] and 
five titanium Greenfield filters with modified hook [TGF-MHs]) were inserted in the 
operating room via an open technique. The remaining 164 VCFs (82%) were inserted in 
the radiology suite by a percutaneous technique (38 SGF, 23 TGF-MH, 51 Vena Tech 
filters [VTFs], 48 Bird's nest filters [BNFs] and 4 Simon Nitinol filters). Thromboembolic 
risk factors in these 196 patients included malignancy (99), trauma (21), recent surgery 
(27)~ cerebrovascular ccident with paralysis (6), and miscellaneous conditions (43). 
Indications for VCF placement included a contraindlcation to anticoagulation (92), 
complication of anticoagulation (44), failure of anticoagulation (26), prophylaxis (31), 
adjunct o pulmonary embolectomy (1), noncompliance (1), hemodynamically unstable 
patient (1), and prior VCF complication (3). Mean follow'up of the patients was 12 
months (range 0 to 87 months). Because there were only four Simon Nitinol filters 
inserted uring the study period, they were excluded from further analysis. 
Results: A comparative analysis revealed that there was a significantly higher incidence of 
symptomatic IVC thrombosis with the use of the BNF (n = 7) (14.6%) versus the SGF 
(n = 0) (0%), TGF-MH (n = 1) (3.6%), or VTF (n -- 2) (4%) (p < 0.05 by chi-squared 
testing). The VCF-related mortality rate was also higher with the BNF (n = 5) (10.9%) 
versus the SGF (n = 1) (1.5%), TGF-MH (n = 1) (3.6%), or VTF (n = 0) (0%) 
(p < 0.05 by chi-squared testing). However there was no significant difference in the 
occurrence of clinically apparent recurrent pulmonary embolism during follow-up 
between the four different filter types (2 [4.2%] BNF, 3 [4.4%] SGF, 1 [3.6%] TGF-MH, 
and 1 [2%] VTF). 
Conclusion: These data indicate that the use of the BNF was associated with increased 
morbidity and mortality rates compared with the use of the SGF, TGF-MH, and VTF 
filters. (J VAsc SURG 1995;21:235-46.) 
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Venous thromboembolism remains a significant 
clinical problem, especially in patients in whom there 
is an incidence of deep venous thrombosis (D'v~) of 
at least 19% to 28%. 1 Additionally pulmonary 
embolism (PE) occurs in 600,000 patients/year in
the United States and results in a 5% mortality rate 
in patients undergoing surgery. 2 Aalticoagulation 
alone is usually adequate therapy in the management 
of  most cases of  DVT and PE; however, under 
certain circumstances anticoagulation may be con 
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traindicated or fail to prevent thromboembolic com- 
plications. 3 In such circumstances vena caval inter- 
ruption is indicated. In addition, vena caval interrup- 
tion may be indicated prophylactically in some 
patients who are deemed at a high risk for develop- 
ment of a PE. 4 Currently, avena caval filter (VCF) is 
the preferred mechanical device for caval interruption 
because of the ease of percutancous insertion and 
proven efficacy, s A variety of VCFs are available for 
usage. The choice usually depends on physician 
preference in addition to specific patient variables, 
such as access ite and caval diameter. In this study 
four types of VCFs were retrospectively compared 
with regard to their efficacy and complication rates. 
PATIENTS AND METHODS 
The medical records of all the patients who under- 
went insertion of a VCF from January 1987 to June 
1993 at the University of Iowa Hospitals & Clinics 
and the affiliated Veterans Administration Medical 
Center were reviewed. Details noted from the med- 
ical records included patient age, sex, medical history, 
thrombocmbolic risk, and thrombocmbolic episode 
preceding the VCF placement. All the relevant diag- 
nostic studies related to the thromboembolic epi- 
sodes, such as venous duplex scans, venograms, com- 
puted tomography scans, ventilation/perfusion scans, 
and pulmonary angiograms, were also evaluated. 
Procedure records of each VCF placement were re- 
viewed for the indication, type of VCF, operative 
technique, site of insertion, venacavogram data, site 
of deployment in the vena cava, and complications. 
Follow-up data were gathered from the medical 
records, clinic notes, outside medical records, and 
telephone interviews with the patients, family mem- 
bers, or the local physician. Major symptomatic com- 
plications related to the VCF such as caval thrombo- 
sis and recurrent PE were analyzed. These major 
complications were documented onthe basis of diag- 
nostic study results uch as results of contrast studies 
of the vena cava, venous duplex scanning, ventila- 
tion/perfusion scanning, or autopsy findings. In 
those patients who died during the follow-up period, 
the cause of death was noted either from the medical 
records or autopsy findings, if available. 
Patient demographics and the duration of 
follow-up of the different types of VCFs were 
analyzed for any statistical difference by analysis of 
variance and Student-Newman-Kuels te t. The un- 
derlying risk factors, thromboembolic episodes, in- 
dications for the VCF placement, and the postpro- 
cedure anticoagulation status between the various 
types of VCFs were compared by chi-squared testing. 
Statistical nalysis of the major symptomatic compli- 
cations and VCF-related mortality between the 
various different types of VCFs was also performed 
by chi-square testing. Ap value less than 0.05 was 
considered statistically significant. 
RESULTS 
One hundred ninety-nine Food and Drug Ad- 
ministration-approved VCFs were inserted in 196 
patients. There were 123 males and 73 females with 
a mean age of 61 years (range 13 to 87 years). 
Eighty-eight percent of these patients were older than 
40 years of age. The underlying risk factors for 
thromboembolism in these patients included malig- 
nancy (n = 99), trauma (n = 21), recent surgical 
procedure (n = 27), cerebrovascular accident with 
paralysis (n = 6), and other miscellaneous condi- 
tions (n = 43). Prior thromboembolic episodes in- 
cluded PE in 105 patients (including 11 recurrent), 
and DVT in 91 (including 12 recurrent). Of the 105 
patients with PE, 48 patients had a documented 
concomitant DVT. PE was diagnosed by "high 
probability" ventilation/perfusion scanning in 75 and 
by pulmonary angiography in the remaining 30 
patients. The diagnosis of DVT was made by use of 
venous duplex scanning in 128 and venography in 11 
patients. The indications for the VCF placement were 
a contraindication (46%), complication (22%), or 
failure (13%) ofanticoagulation, prophylaxis (16%), 
and miscellaneous (3%). The miscellaneous indica- 
tions included prior VCF complication in three, 
adjunct to pulmonary embolectomy in one, noncom- 
pliance with anticoagulation therapy in one, and 
hemodynamic instability with PE in one patient. 
One hundred ninety-two VCFs were placed 
electively in the infrarenal position and seven filters 
were electively deployed in the suprarenal cava (four 
Vena Tech filters [VTF], two stainless teel Green- 
field filters [SGF], one Bird's nest filter [BNF]). The 
indications for deployment in the suprarenal position 
were inadequate space because of inferior vena cava 
(IVC) thrombus in six, and infrarenal IVC throm- 
bosis (IVCT) as a result of a previous VCF device in 
one patient. When the outcome of these seven 
patients with the suprarenal filters was analyzed, it
was found that five patients had died because of their 
underlying medical condition (metastatic disease in 
three, existing PE in one and multisystem organ 
failure in one) and one died because of complications 
from IVC thrombosis related to a previous VCF. The 
six patients who died had been monitored for 1 to 56 
days (median 5 days). Only one patient with a VCF 
in the suprarenal position was alive and doing 
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well without any complications at 38 months of fol- 
low-up. 
Table I depicts the different ypes of VCFs that 
were inserted in this patient population. These 
included the stainless steel Greenfield filter (SGF) 
(Medi-tech/Boston Scientific Corporation, Water- 
town, Mass.), the titanium Greenfield filter with 
modified hook (TGF-MH) (Medi-tech/Boston Sci- 
entific Corporation), the Vena Tech filter (VTF) (B. 
Braun Vena Tech, Evanston, Ill.), the Bird's nest filter 
(BNF) (Cook Inc., Bloomington, Ind.), and the 
Simon Nitinol filter (SNF) (Nitinol Medical Tech- 
nologies, Inc., Woburn, Mass.). These filters were 
inserted under the supervision of 12 staff physicians 
(five vascular surgeons and seven interventional 
radiologists). Three patients had two VCFs inserted. 
Two SGFs were inserted in one patient under the 
same anesthesia because the initial filter was mis- 
placed into the right common iliac vein. A second 
filter was then appropriately placed in the infrarenal 
IVC. Another patient had development of IVC 
thrombosis 12 days after the successful deployment 
of a VTF, and a BNF was then placed in the 
suprarenal position. The third patient had a mis- 
placed BNF that had to be removed after its 
migration and perforation of the common femoral 
vein. Another BNF was inserted in this patient 4 
months later. Thus 199 VCFs were placed in 196 
patients on 198 separate occasions. In addition, in 
one other patient an experimental prototype tempo- 
rary filter was inserted into each iliac vein. These two 
devices were later removed when thrombosis devel- 
oped around them at 5 days, and the patient received 
a VTF positioned in the suprarenal cava. Because 
these were prototype devices, they are excluded from 
further analysis. 
There were only four SNFs inserted in this patient 
population. The indications for placement of these 
four SNFs were a contraindication to anticoagulation 
in three and a complication of anticoagulation in one. 
The thromboembolic episode before their placement 
was PE in three patients and DVT in one patient. The 
SNFs were placed via the right femoral vein in two, 
left femoral vein in one, and right internal jugular 
vein in one. All of them were placed in the infrarenal 
location and the size of the IVCs measured 15 _+ 
2 mm. No patient with a SNF received anticoagula- 
tion after insertion. These four patients were moni- 
tored for a mean duration of 5 months (range 0.5 to 
8 months). No complications related to the filter 
were identified. One patient died 45 days after filter 
insertion because of metastatic disease from esoph- 
ageal carcinoma. The four patients with a SNF were 
Table I. Types of vena caval filters placed 
No. (%) 
SGF 68 (34) 
TGF-MH 28 (14) 
VTF 51 (26) 
BNF 48 (24) 
SNI~ 4 (2) 
excluded from further analysis because the numbers 
were too few to give meaningful data in terms of 
efficacy and complications. 
Thirty-five (18%) VCFs were inserted via the 
right internal jugular vein by an open technique. 
These comprised 30 SGFs and five TGF-MH filters. 
The remaining 160 (82%) VCFs were inserted by a 
percutaneous technique (38 SGF, 23 TGF-MH, 51 
VTF, and 48 BNF). Thirty-five of' these were 
percutaneous insertions via the right internal jugular 
vein, 109 via the right femoral vein, and the 
remaining 16 via the left femoral vein (Table II). All 
the VCFs inserted by the vascular surgeons were 
either SGFs (30) or the TGF-MH filters. 
Anticoagulation was continued or restarted in 52 
(26%) of cases, either several hours after filter 
placement or within 2 weeks when there was no 
longer an absolute contraindication to anticoagula- 
tion. The anticoagulation was usually continued if 
possible for up to 3 to 6 months. 
A contrast study of the IVC done before the 
insertion of each VCF was available for review in 165 
(85%) cases. In the remaining 30 cases (27 SGF and 
3 TGF-MH), the venacavogram was either not 
obtained or not available because of film purging or 
lack of hard copy films during fluoroscopic place- 
ment. The diameter of the IVC at the site of filter 
insertion in these 162 patients were as follows for 
each filter: SGF 20 + 5 ram, TGF-MH 18 _+_ 4 ram, 
VTF 18 _+ 5 ram, and BNF 20 _+ 5 mm. There was 
no statistical difference in the diameter of the IVC 
between the various types of filters (by ANOVA and 
Student Newman Kuels test). 
Mortality and morbidity 
The patients were monitored for a mean duration 
of 12 months (range 0 to 87 months). Ninety-three 
patients (48%) died during the follow-up period, and 
autopsy findings were available in 15 (five with 
BNFs, six with SGFs, one with a TGF-MH, and three 
with VTFs). Ninety-two percent of the deaths were 
due to the underlying medical condition or concur- 
rent illness, and the remaining 8% were due to 
VCF-related complications. Seventeen patients died 
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Table II. Insertion sites of the various VCFs 
Right internal jugular Percutaneous 
Open Percutaneous Right femoral Left femoral 
SGF 30 16 21 1 
TGF-MH 5 10 12 1 
BNF 0 3 34 11 
VTF o ~ 4__~2 3 
Total 35 35 109 16 
within 30 days of the fiker placement (five because of 
VCF-related causes, 12 because of underlying pri- 
mary disease). The remaining 76 deaths occurred 
beyond 30 days after filter placement ( wo because of 
VCF-related causes, 74 because of underlying pri- 
mary disease). The placement of a BNF was associ- 
ated with a significantly higher complication rate 
(25%) than that of the SGF, TGF-MH, and VTF. 
Death directly related to a complication associated 
with the VCF occurred in 7 of 192 patients (3.6%). 
Four of the patients died because of complications a
a result of IVC thrombosis and the other 3 patients 
died because of a PE despite the presence of a filter. 
The BNF had a significantly higher VCF-related 
mortality rate compared with the SGF, TGF-MH, or 
VTF. 
Patient demographics, indications for filter place- 
ment, length of follow-up, and outcomes of the 
patients with each type of VCF are depicted in Table 
III. These data were comparable between the differ- 
ent filters except for the duration of follow-up, which 
was shorter for the patients with BNFs. 
Major symptomatic omplications after VCF 
placement occurred in 21 of 195 (10.8%) cases (192 
patients) and are depicted in Table IV. All of these 
VCFs were positioned in the infrarenal location. 
Symptomatic IVC thrombosis (IVCT) after a VCF 
placement occurred in 10 cases (5.1%) from 2 days 
to 7.5 months (median 26 days) after the VCF 
placement. In seven patients, it was detected within 
30 days after the VCF placement, and in the other 
three patients it was diagnosed at 3, 6, and 7.5 
months, respectively. The presenting feature of 
symptomatic IVC thrombosis in these 10 patients 
was acute renal failure as a result of extension of 
thrombosis into the renal veins in five, phlegmasia 
cerulea dolens in four, and superior vena caval (SVC) 
syndrome inone. In the latter patient thrombosis was 
present in both the superior and inferior vcna cava. 
When the data were analyzed for the different types 
of filters, the incidence of complications was found to 
be significantly higher for BNFs (14.6%) compared 
with SGFs (0%), TGF-MHs (3.6%), or VTFs (4%) 
(p < 0.05, by chi-squared testing) (Table V). 
In the BNF group with symptomatic IVC throm- 
bosis, the clinical presentation was acute renal failure 
as a result of extension of thrombosis into the renal 
veins (n = 4), phlegmasia cerulea dolens (n = 2), 
and an associated SVC syndrome (n = 1). All four 
patients who had development of acute renal failure 
were treated without operation and died as a result of 
renal failure. Hence, the mortality rate was 57% in 
patients with a BNF who had development of 
symptomatic IVC thrombosis. One patient with 
phlegmasia cerulea dolens underwent an iliofemoral 
venous thrombectomy and four-compartment fas- 
ciotomy. He was then maintained on anticoagulation 
for 6 months. The second patient with phlegmasia 
cerulea dolens in the BNF group was treated with 
anticoagulation alone but died as a result of sepsis 
from bilateral pneumonia. The patient with the 
associated SVC syndrome was treated with antico- 
agulation and steroids (for cerebral edema) but 
succumbed because of widespread metastatic disease. 
The patient with a TGF-MH who had development 
of symptomatic IVC thrombosis was diagnosed with 
phlegmasia cerulea dolens but died because of his 
underlying renal cell carcinoma. One of the two 
patients with a VTF and symptomatic IVC throm- 
bosis was diagnosed with phlegmasia cerulea dolens. 
The other patient who had development of acute 
renal failure had a BNF placed in the suprarenal 
position after the onset of the renal failure. This 
patient died 1 day later because of sepsis/adult 
respiratory distress yndrome, which had developed 
unrelated to the IVC thrombosis and renal failure. 
There was no death because of IVC thrombosis nthe 
one patient with a TGF-MH and the two patients 
with a VTF who had symptomatic IVC thrombosis. 
Five patients (2.6%) with clinically apparent 
recurrent PEs were diagnosed before death during 
the follow-up. Recurrent PE was confirmed at 
autopsy in two of these five patients. In another two 
patients PE was diagnosed only at the time of 
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Table III. Patient demographics, indications and outcomes of the different VCFs 
SGF TG~ FCF BNr 
Age (yr.) 63 + 15 58 + 16 60 + 15 63 ± 16 
Male:Female ratio 44:23 18:10 30:21 29:17 
Risk factors: 
Malignancy 35 (5:2%) I3 (46%) 24 (47%) 25 (54%) 
Recent surgery 5 (8%) 5 (18%) 8 (16%) 8 (17%) 
CVA with stroke 2 (3%) 1 (4%) 2 (4%) 0 (0%) 
Trauma 10 (15%) 3 (11%) 5 (10%) 3 (7%) 
Miscellaneous 15 (22%) 6 (21%) 12 (23%) 10 (22%) 
T-E Episodes: 
DVT 38 (57%) 10 (36%) 22 (43%) 20 (43%) 
PE 29 (43%) I8 (64%) 29 (57%) 26 (57%) 
Iliac vein thrombosis 3 (4%) 2 (7%) 3 (6%) 2 (4%) 
Indications: 
Contraindication to AC 28 (41%) 13 (46%) 25 (49%) 23 (48%) 
Complication ofAC 14 (21%) 6 (21.5%) 13 (25%) I0 (21%) 
Failure of AC 8 (12%) 6 (21.5%) 7 (14%) 5 (10%',1 
Prophylaxis 16 (23%) 3 (11%) 6 (12%) 6 (13%) 
Miscellaneous 2 (3%) 0 (0%) 0 (0%) 4 (8%) 
Post-procedure AC 24% 36% 29% 31% 
Follow-up (mos.) 
Median 4.25 6 6 2.25 
Range 0.03 to 87 0.06 to 53 0 to 53 0.03 to 42 
Deaths (Follow-up eriod) 30 (45%) 11 (39%) 22 (43%) 30 (65%) 
CVA, Cerebrovascular accident; T-E, thromboembolic; AC, anticoag~alation 
autopsy. All seven recurrent episodes of PE devel- 
oped between 4 days and 17 months (median 12 
days) after the insertion of the VCF. PE was the cause 
of death in three of the seven patients (43%) with 
recurrent PE. Two patients with a BNF had devel- 
opment of recurrent PE. One died of PE and the 
other patient died as a result of Pseudomonas pneu- 
monia. Of the three patients with recurrent PE in the 
SGF group, one died of a fatal PE. The other two 
patients died because of respiratory failure (caused by 
aspiration pneumonia) and metastatic disease. The 
one patient with a TGF-MH who had development 
of a recurrent PE died after that episode. Only one 
patient with a VTF had development of a recurrent 
PE. However, he died because of severe left ventricu- 
lar failure and pulmonary edema. By chi-squared 
testing there was no significant difference in the 
incidence of recurrent PE after the insertion of the 
various types of VCFs (BNF 4.2%, SGF 4.4%, 
TGF-MH 3.6%, and VTF 2%). 
Patients in whom the VCF was placed because of 
a complication of anticoagulation had a significantly 
higher incidence of symptomatic IVC thrombosis 
than when it was inserted for other indications (14% 
vs 2.5%,p < 0.05 by chi-squared testing). Similarly, 
despite receiving anticoagulation after the VCF 
placement, a significantly higher number of patients 
had development of symptomatic IVC thrombosis 
compared with those who were not given anticoagu- 
lant after the procedure (13% vs 2%, p < 0.05 by 
chi-squared testing). Patients with BNFs who were 
maintained on anticoagulation therapy had a higher 
incidence of symptomatic IVC thrombosis compared 
with those patients who did not receive any antico- 
agulation therapy (33% vs 6%, p < 0.05 by chi- 
squared testing). Similarly, clinically apparent recur- 
rent PE developed more often in patients with SGFs 
who underwent postprocedure anticoagulation 
therapy compared with those patients who did not 
receive anticoagulants after the procedure (19% vs 
O%,p < 0.05 by chi-squared testing). There was no 
significant difference in the incidence of symptomatic 
IVC thrombosis or recurrent PE with or without 
anticoagulation among the other three ~pes of VCFs 
studied, and there was no difference inthe occurrence 
of clinically apparent recurrent PE with regard to the 
indications for VCF placement or postprocedure 
anticoagulation status. 
Because of the high incidence of symptomatic 
IVC thrombosis associated with the BNF found in 
this study, we critically evaluated all the post:filter 
placement venacavograms in this group. In the 47 
BNFs that were placed in the infrarenal position, the 
superior aspect of the cephalad struts of the BNFs 
were indeed below the level of the renal veins in all 
cases. However, the upper end of the wires of the 
filter were not always found to lie at or below the 
upper ends of the cephalic struts (Fig. 1). Hence, we 
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Table IV. Complications of VCF placed 
Patient VCF Indication PostVCF Time of VCF-related Diagnosis of 
no. type for VCF anticoagulation occurrence complication complication Outcome 
1 BNF Complication of an- VQ scanning Death (unrelated) 
ticoagulation 
2 BNF Complication of an- 
ticoagulation 
3 BNF Contraindication f 
anticoagulation 
4 BNF Complication of an- 
ticoagulation 
5 BNF Contraindication f 
anticoagulation 
BNF Contraindication f 
anticoagulation 
BNF Contraindication f 
antlcoagulation 
BNF Failure of anticoagu- 
lation 
BNF Contraindication f 
antlcoagulation 
BNF Contraindication f 
anncoagulation 
BNF Contraindication f 
antmoagulation 
BNF Complication of an- 
ticoagulation 
SGF Contraindication f 
anticoagulation 
SGF Contraindication f 
anticoagulation 
SGF Complication of an- 
ticoagulation 
SGF Contraindication f 
anticoagulation 
TGF-MH Contraindication f 
anticoagutation 
TGF-MH Contraindication f Duplex 
anticoagulation 
VTF Failure of anticoagu- Autopsy 
lation 
VTF Complication of an- Duplex Alive 
ticoagulation 
VTF Prophylactic 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
No 9 days Rec. PE 
No 7 days Rec. PE 
No 20 days IVCT 
Yes 26 days IVCT 
Yes 7.5 months IVCT 
No 26 days IVCT 
Yes 2 days IVCT 
Yes 20 days IVCT 
Yes 3 months IVCT/SVCT 
No At deployment Misplacement 
Yes At deployment Misplacement 
No At deployment Misplacement 
No 4 days Rec. PE 
No 12 days Rec. PE 
No 40 days Rec. PE 
No At deployment Misplacement 
Yes 3 months Rec. PE 
No 6 months IVCT 
No 17 months Rec. PE 
Yes 30 days IVCT 
Yes 12 days IVCT 
VQ scan/autopsy PE (death) 
Duplex/autopsy Kidney failure 
(death) 
Duplex Death (unrelated) 
Duplex Kidney failure 
(death) 
Duplex Kidney failure 
(death) 
Venography Alive 
Duplex Kidney failure 
(death) 
Venography Death (unrelated) 
Venography No further sequelae 
Venography No further sequelae 
Venography/CT Migration/penetra- 
scanning tion-femoral vein 
Autopsy PE (death) 
VQ scanning Death (unrelated) 
VQ scanning/au- Death (unrelated) 
topsy 
Radiology/venog- Another SGF 
raphy placed 
VQ scanning PE (death) 
Death (unrelated) 
Death (unrelated) 
Duplex/autopsy Death (unrelated) 
Rec., Recurrent ; VQj ventilation/perfusion; SVCT, superior vena cava thrombosis. 
classified the BNFs in this series as "prolapsed-BNF", 
as defined by extension of the wires above the level of 
the cephalad struts, and "compact-BNF", where the 
wires remained below the level of the cephalad struts. 
Prolapsed BNFs were seen in 17 cases (36%). The 
length of prolapse of the wires beyond the cephalad 
struts in these prolapsed BNFs was 23 + 14 mm. 
However, in seven of these 17 cases (41%), the upper 
end of the prolapsed wires was still below the level of 
both renal veins (infrarenal prolapse). In the remain- 
ing 10 instances, the prolapsed wires had extended 
beyond the level of the renal veins into the suprarenal 
IVC (suprarenal prolapse) (Fig. 2). Six of the 10 
suprarenal prolapsed BNFs developed symptomatic 
IVC thrombosis. This was significantly higher than 
that which occurred when the filter did not have a 
suprarenal prolapse of the wires (p < 0.05, by 
&i-squared testing). 
DISCUSSION 
Appropriate arly diagnosis and effective initial 
management of DVT and PE aims to limit further 
morbidity and lessen the mortality associated with 
thromboembolism. The primary therapy for DVT or 
PE is anticoagulation, initially with intravenous 
heparin followed by a maintenance dose of oral 
warfarin for at least 6 weeks and usually for 3 to 6 
months? There are, however, always subsets of 
patients in whom anticoagulation is contraindicated, 
has failed, or caused complications. In these patients 
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Fig. 1. Plain radiograph of abdomen shows BNF with upper ends of wires lying above level 
of cephalic struts. Arrow points to wires. 
interruption of the passage of major emboli to the 
pulmonary circulation is indicated to prevent death 
from PE. Historically these patients were tradition- 
ally treated surgically by ligation of the IVC below 
the renal veins. 68 A variety of techniques involving 
plication, sieving the vena cava or the use of 
extracaval clips later evolved. 9"14 A major disadvan- 
tage of the use of these operative methods was that 
many of these patients were elderly or frail or had 
severe comorbid illnesses that not only precipitated 
the thromboembolic episode but also placed them at 
a high operative risk for the surgical procedure. 
Direct surgical techniques have been almost 
exclusively superseded by the use of a variety of 
transvenous filter devices that have been developed 
over the past two decades. 15-19 The VCFs that are 
currently available for clinical use come in various 
sizes and configurations, with proponents claiming 
superiority of one filter over others with regard to 
clot-trapping ability and long-term caval patency. 
The development of the Mobin-Uddin umbrella 
in 1967 started the modern era of transvenous caval 
interruption.18 The Mobin-Uddin umbrella was usu- 
ally inserted via the right internal jugular vein and 
came initially in a 23 mm diameter size. 19 Potentially 
lethal migration of this device prompted the devel- 
opment of the larger 28 mm diameter umbrel la.  2°,2I 
The Mobin-Uddin umbrella has a high late caval 
occlusion rate possibly, up to 73% and, hence, is not 
favored by most clinicians because of the availability. 
of alternative filters with higher caval patency rates.22 
The SGF was introduced in 1972. ~ The conical 
shape of this filter is said to be beneficial ira 
maintaining circumferential f ow through the vena 
cava despite progressive central filter occlusion. Prior 
studies have shown that this device effectively traps 
emboli 3 mm or greater in diameter. 23 Tilting of the 
device reduces the clot trapping efficiency and may be 
seen in up to 1.7% of cases. 24 The SGF has a reported 
4% rate of recurrent embolism, while maintaining a
long term caval patency over  95%.  22,25-27 The SGF 
comes with a 24F carrier system and hence was 
traditionally placed operatively with a jugular or 
femoral cut down. Use of a large (28F) sheath did 
allow for percutaneous introduction. When the 
device was inserted through the femoral vein, there 
was a reported 41% incidence of insertion-site 
femoral vein thrombosis. 28 Hence, most of these 
devices were usually inserted via the jugular vein. 
When the vena cava is large ( > 30 mm in diameter), 
separate SGFs are recommended for insertion into 
each iliac vein, 29,3° A titanium model of the Green- 
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Fig. 2. Postfilter placement vena cavogram reveals suprarenal prolapse ofBNF; RV, renal vein; 
BNF, Bird's nest filter in IVC; Arrow points to prolapsed wires. 
field filter (TGF) was developed in 1987 to decrease 
the carrier system to a 12F size to facilitate percuta- 
neous placement through a 14F sheath, alA recurved 
hook design with a twist to 80 degrees was required 
in the current model of the TGF (TGF-MH) to 
facilitate better fixation to the caval wall and prevent 
distal slippage. 32 In a multicenter t ial involving 186 
patients, recurrent PE (3%), insertion site venous 
thrombosis (9%), incomplete opening (2%), and 
asymmetry of the legs (5%) were noted with this 
modified version, while maintaining a 100% filter 
patency rate. 33 
In 1977, a filter device made from nitinol 
(nickel/titanium alloy) was described. The SNF has 
the smallest carrier system (TF) of all filter devices 
and, hence, can be introduced through an antecubital 
vein. A SNF may be useful for patients who have a 
relative contraindication to a jugular approach, such 
as severe orthopnea, a very short neck, or other 
anatomic abnormalities and in whom the femoral 
approach is not feasible because of ilio/femoral vein 
thrombosis. After a decade of clinical experience with 
the SNF, the reported caval occlusion rate is 18%, 
and misplacement of the filter is 3%. a4 
The Amplatz filter (William Cook Europe, 
Bjaerverskov, Denmark) is a device made from 
stainless teel alloy with an attached hook at one end 
to allow retrieval or repositioning. Even though it 
had excellent clot trapping efficacy because of its 
dense arrangement of wires, the rate of vena caval 
occlusion was 21%. 35 This device is still considered to 
be in a developmental stage. 
The VTF was introduced to the market in 1986. 
Originally developed in France as the LGM filter (La 
Medical, Chassneuil, France), the VTF, as it is known 
in the United States, is made of Phynox, a material 
similar to that used in temporary" cardiac pacing 
wires. The VTF is introduced through a 12F sheath. 
This device has an IVC thrombosis rate of 4% to 
30%. 36.40 Incomplete opening of the VTF has been 
reported in 8% to 41% of transjugular insertions, 
and, hence, it is recommended that this route should 
be avoided if possible. 36'4I'42 
Roehm et al. 43 reported the first use of the BNF 
in 1984. This filter was approved for clinical use by 
the United States Food and Drug Administration i
1989. It consists of four stainless teel wires pre- 
shaped into a crisscrossing array of nonmatching 
bends. In its initial design, each of these wires was 25 
cm long, 0.18 mm in diameter and ended in a 0.25 
mm flexible strut connected to a hook. When 
inserted, two struts are arranged in a V-shaped 
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Table V. Comparison of the complications of VCFs 
SGF TGF-MI-I VTF BNF 
Symptomatic IVC thrombosis 0% 1 (3.6%) 2 (4%) 7 (14.6%) ~ 
Recurrent PE 3 (4.4%) 1 (3.6%) I (2%) 2 (4.2%) 
Misplacement 1 (1.5%) 0% 0% 3 (6.3%) 
VCF-related eath 1 (1.5%) 1 (3.6%) 0% 5 (I0.9%)* 
*Significantly higher than SGF, TGF-MH, or VTF by chi-squared testing, p < 0.05. 
manner cephalad, with the other two in an inverted 
V-shaped manner caudad. The original model came 
preloaded in an 8F polytetrafluoroethylene sheath. In 
1986, the device was modified with a stiffer 0.46 mm 
strut to improve the fixation to the vena cava walls 
and limit migration. The modification ecessitated 
preloading the BNF in a 12F sheath. The BNF 
produces a crisscross nest of 100 cm of 0.18 mm 
wires over an average length of 7 cm of the IVC. This 
unique design of the BNF allows it to be placed in an 
IVC that measures up to 40 mm in diameter. 44 In one 
series reported in 1988, in which 440 patients had 
been monitored for more than 6 months, the 
reported incidence of clinically suspected recurrent 
PE was 2.7% and the IVC occlusion rate was 2.9%. 45 
However, only 37 of these 440 patients were studied 
by venacavography or ultrasonography. Seven of 
these 37 patients (19%) had a caval occlusion. 
Another study reported a 21% rate of vena caval 
thrombosis after placement of a BNF. 4° The modi- 
fication with a stiffer strut appeared to prevent 
migration of the filter, which had occurred in some 
patients who had the original device. One of the 
problems with the design of the BNF is that exmasion 
of the filter is operator dependent. Depending on the 
mode of deployment, several wires may "prolapse" 
beyond the cephalic V-struts fixed in the IVC. A 
prolapsed BNF (defined as the length of the filter 
wires beyond the longer limb of the cephalic V-strut 
or approximately 6 cm from the center of the V-strut) 
remains effective for clot trapping. 4648 The incidence 
of BNF prolapse reported varies from 8% to 
45%.  a1'47'49 The results of our study suggest that a 
prolapsed BNF is still effective for clot trapping, 
because there was no incidence of clinically apparent 
recurrent PE in any of our 17 prolapsed BNFs. On 
the contrary, the two cases of recurrent PE associated 
with the BNF occurred with a "compact BNF." 
These two cases of recurrent PE were documented by 
new findings on the ventilation/perfusion scans, and 
confirmed further by autopsy in one of them. The 
significant finding in this report is that symptomatic 
IVC thrombosis occurred in 60% of cases with a 
suprarenal prolapse of the BNF. Only one case of 
symptomatic IVC thrombosis occurred in the "com- 
pact BNF" group, which is a comparable finding with 
the other types of VCF devices. The prolapse of the 
wires of the BNF may be an operator-dependent 
phenomenon. In our opinion the BNF is technically 
more difficult o deploy correctly than the other types 
of VCFs. Our view is supported by the reported 
experience of Vesely et al.,49 who reviewed the 
technical problems with the placement of 165 BNFs. 
It is possible that the operators learning curve could 
have contributed to the incidence of prolapse of the 
BNF and, hence, the increased morbidity and mor- 
tality rates. Comparatively the other three VCFs 
analyzed in this study (i.e., SGF, TGF-MH, and 
VTF) were not as susceptible to technical problems 
at the time of deployment. 
The BNF had a higher caval thrombotic ompli- 
cation rate at our institution compared with the VTF, 
SGF, and the TGF-MH devices. The VTF performed 
satisfactorily in our hands, but the complication rates 
in published series are substantial. Based on our own 
more limited experience and the reports of low 
morbidity in a large muM-center series, the TGF-MH 
is our current filter of choice. In patients who need 
vena caval interruption for prophylaxis, we specifi- 
cally prefer the TGF-MH because of  its safety, ease of 
placement, and low incidence of complications. 
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DISCUSSION 
Dr. George Johnson, Jr. (Chapel Hill, N.C.). Dr. 
Mohan presented the data in a well-organized and succinct 
fashion. However, the data presented id nothing to 
support my bias to favor Greenfield filters over other filters. 
It is difficult to randomize this type of study, and therefore 
any conclusions drawn from these data are merely specu- 
lative. There are many variables, including the use of five 
different ypes of devices in these patients. I assume there 
was no protocol for which device was used. There is 
considerable variation in number of each type of filter that 
was evaluated. The number of physicians involved, and 
certainly the device, although not stated, must be large. 
Fifteen percent of the preoperative phlebograms were 
not available. Thus we really don't know how many of the 
patients had an IVCT before the procedure. 
The insertion of an IVC device from the groin has been 
reported to be associated with more iliofemoral thrombosis 
than other sites. I could not determine the number of BNFs 
inserted from the groin that had complications versus the 
number of Greenfield filters inserted from the groin that 
had complications. 
With the relatively small number of BNFs and VTFs 
inserted, is it possible that the technique for insertion of 
these filters was still in the learning process for a number of 
instances? 
How many of the Greenfield filters were inserted 
prophylactically? One expects and hopes that the compli- 
cations would be less in the prophylactic nsertions. 
It is interesting to see the large number of patients who 
had development ofrenal failure after insertion of the BNF. 
They did try to address this in their presentation, but is this 
unique to this device? Or is this because of inappropriate 
technique in inserting the device? 
It is interesting to note in Table IV that 18 of the filters 
were inserted for complications of or contraindications to 
anticoagulant therapy. Yet seven of the patients were 
subsequently given anticoagulant. Could it be that the 
filters were not indicated in the first place? 
Thus these data have all the defects that accompany a 
retrospective study. I believe John Porter would let me 
apply a Sachett level four to this study. As many of you 
know, I believe the incidence of death from PE, although 
certainly present, is overemphasized. However, I strongly 
believe in prophylaxis. I do question the filter as a 
prophylactic measure. 
This study represents a lot of work. It will be quoted 
extensively. The information is sorely needed, and it's 
probably one of the best documents we have evaluating the 
various IVC filters. Un~brtunately, these data, like other 
data on PE, don't convince me that my prejudice in favor 
of the Greenfield filter is correct. 
Dr. John D. Corson. There was no specific protocol 
for filter selection. The filters were placed by a varieB, of 
different physicians. As you correctly point out, there may 
be a learning curve in the use of the various devices. A 
device that is safe and has a simple standardized insertion 
technique is highly desirable. 
As noted in the text, the majority but not all the 
venacavograms were available for late review. However, 
none of the patients who had an infrarenal filter placed had 
evidence ofcaval thrombosis at the time of filter placement, 
With regard to the question of posnCilter placement IVC 
thrombosis, all the patients with a BNF who had devel- 
opment of IVC thrombosis had the filter placed via a 
femoral approach. Only one patient with a TGF subse- 
quently had development of an IVCT. In this patient he 
filter had been placed via a jugular approach. The site of 
insertion of the different ypes of filters are depicted in 
Table III. We did not specifically look at the incidence of 
insertion site thrombosis in this retrospective study. 
In response to Dr. Johnston's question concerning 
prophylaxis, only 16% of the filters were placed fbr this 
indication. To justify the use of a filter for prophylaxis, it
must have minimal morbidity. Our data, as well as those in 
other reports, demonstrate hat there is a significant caval 
thrombosis rate after insertion of certain filters. If you elect 
to place a filter for prophylaxis, you should choose the filter 
that has the least morbidity and the lowest caval thrombosis 
rate. The Greenfield filter appears to have a lower incidence 
of caval thrombosis compared with the others. 
Dr. Johnston pointed out that 92 (46%) of the patients 
had a contraindication to anticoagulation as the indication 
for filter placement. The threshold for filter placement is
quite variable ven between colleagues at our own institu- 
tion in this regard. Of interest, 53 (26%) of the patients 
were given anticoagulant again after filter placement, We 
believe that there is some benefit in limiting lower 
extremity thrombus propagation by maintaining the pa- 
tient on anticoagulation therapy after filter placement, 
provided that it can be given safely. 
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Vascular surgeons may have little control over the 
treatment of patients with thromboembolism, any of 
whom are referred irectly to an interventional radiologist. 
I would make a plea that surgeons remain closely involved 
in all aspects of the treatment of patients with venous 
thromboembolism. We are the primary care doctors for 
vascular disease and know more about DVT and its 
complication than most other physicians. 
Dr. Lazar I. Greenfield (Ann Arbor, Mich.). All of us 
would like to see a randomized prospective study that 
would produce some data for comparison purposes. Unfor- 
tunately, when we look to the reports of alternative filters, 
it's very difficult o find comparable follow-up information. 
Many of them appear to have incidences of vena caval 
thrombosis n the range of about 20%, which is what seems 
to be occurring in this particular series with the BNF. 
What do you do to treat the patient who has 
development of vena caval thrombosis at the level of the 
filter? The concern is not just for the stasis sequelae, but the 
fact that this then becomes anidus for new thrombus that 
can propagate and become a new source of embolism. 
Consequently these patients acquire a new risk of recurrent 
embolism based on that level of thrombosis. 
Dr. Corson. Thrombolysis may have a limited role by 
lysing impacted thrombus at the filter level and restoring 
caval patency. Presumably, unless patients were being 
screened routinely, only patients with symptoms would be 
seen with this problem. The treatment would be deter- 
mined by their symptoms and the ability to tolerate a 
further course of anticoagulation. An additional question 
might be what to do when you realize that a BNF has been 
put in with the wires prolapsing above the renal veins. 
Clearly those patients had a high mortality rate in our 
series. Obviously if you can maintain them with a 
reasonable level of anticoagulation, that would seem 
appropriate for the initial management of this problem, 
provided anticoagulation was not contraindicated. One 
hopes that with appropriate anticoagulation you could 
limit the problem of renal vein thrombosis. The thought of 
trying to remove a BNF that has prolapsed up above the 
level of the renal veins is a bit adventurous. We are not 
certain why renal vein thrombosis occurred in our series. It 
is possible that renal vein thrombOsis occurred because of 
local hemodynamics in that area. The other possibility is 
that a propagated DVT on its way to the ltmgs impacted 
at the filter site and caused caval thrombosis with propa- 
gation to the renal veins. 
Dr. Arie L. Markel (Haifa, Israel). I have a question 
that has to deal with insertion of IVC filters in patients 
who already have thrombosis in the IVC. Recently we 
treated a 66-year-old man, who was admitted to our 
Internal Medicine Department with a clinical and lung 
ventilation/perfusion scanning diagnosis of PE. Further 
investigation showed a left renal tumor that extended into 
the IVC. Computed tomography scanning and duplex 
ultrasonography showed a large thrombus (tumor?) in the 
IVC that extended proximally near the diaphragm. Hep- 
arin was started, but the patient had development of a 
massive left iliac thrombosis that was treated by streptold- 
nase and then warfarin. After thrombolytic therapy was 
stopped, the patient had development of a huge retroperi- 
toneal hematoma. Hepatin was stopped and an IVC filter 
was suggested before surgery. 
Could a filter be inserted when a large thrombus is 
present in the IVC? What are the limitations to filter 
insertion in this area? 
Dr. Corson. Clearly, you can put in a suprarenal filter 
safely if there is adequate space for insertion. This is why 
you need to individualize filter choice for each patient, 
depending on the size of the cava and the amount of space 
available for filter deployment. There is enough experience 
with Greenfield filters placed above the renal veins to show 
that it is relatively safe in these rather difficult circum- 
stances. 
Dr. Markel. But in this case the thrombosis was near 
the hepatic veins. 
Dr. Corson. If there is no space available you cannot 
place a filter. In certain cases, lysis might allow filter 
placement, but in your case this was not an option. A direct 
surgical approach with thrombectomy would have to be 
considered. 
